Novo eyes early 2027 US CagriSema launch after 21% weight loss in REDEFINE 9
ad-hoc-news · · AI-summarised by FinFlash
Novo Nordisk's CagriSema delivered 21% weight loss at week 68 in the REDEFINE 9 trial, with a possible US launch in early 2027, alongside third-quarter results that lifted the 2026 outlook. Adjusted sales and operating profit are now guided to between minus 2% and plus 2% at constant currencies, from minus 6% to zero. Reported operating profit fell 9% to DKK 23.0 billion after impairments. The shares traded at 37.11 euros at midday.
So What?
CagriSema gives Novo a next-generation obesity catalyst to pair with its Wegovy pill. Watch US regulatory timing and competition from rival drugmakers.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.